Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $896.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 35.54% year-over-year to $896.1 million; the trailing twelve-month figure through Jun 2026 stood at $3.2 billion (up 33.43% YoY), and the FY2025 full-year result was $763.6 million, up 31.54% from the prior year.
• Liabilities and Shareholders Equity rose to $896.1 million in Q2 2026 per KNSA's latest filing, from $825.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $896.1 million in Q2 2026 and bottomed at $210.6 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $553.0 million across 5 years, with a median of $534.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity decreased 25.77% in 2022, then surged 130.0% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $459.7 million in 2022, then climbed by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then jumped by 31.54% to $763.6 million in 2025, then rose by 17.35% to $896.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $896.1 million, $825.3 million, and $763.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.